Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

Overview of attention for article published in Frontiers in immunology, April 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 32,811 followers.

New Research: Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study: Introduction The treatment for… https://t.co/Tn44N4JcyQ #imm

04 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.